Results 41 to 50 of about 3,746,463 (320)

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Antirheumatic drugs and reproduction in women and men with chronic arthritis. [PDF]

, 2015
The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients' sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a
Agosti, M, Andreoli, L, Bazzani, C, Nalli, C, Tincani, A   +4 more
core   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources

COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs

Annals of the Rheumatic Diseases, 2020
We read with interest the article by Monti et al ,1 who evidenced, in a cohort of subjects affected by COVID-19, a low prevalence of patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying
E. Conticini, E. Bargagli, M. Bardelli, G. D. Rana, C. Baldi, P. Cameli, S. Gentileschi, D. Bennett, P. Falsetti, N. Lanzarone, F. Bellisai, C. Barreca, R. D’Alessandro, L. Cantarini, B. Frediani   +14 more
semanticscholar   +1 more source

Treatment of experimental amyloidosis with antirheumatic drugs

Acta Medica Lituanica, 2010
Background. Because at present there is no known specific effective therapy for secondary amyloidosis, the aim of this study was to determine whether antirheumatic drugs inhibit the development of experimental AA amyloidosis induced in C57BL/6 mice by ...
Laima LEONAVIČIENĖ, Danutė POVILĖNAITĖ, Rūta BRADŪNAITĖ, Dalia VAITKIENĖ, Algirdas VENALIS   +4 more
doaj   +1 more source

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Annals of the Rheumatic Diseases, 2013
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated.
J. Smolen, R. Landewé, F. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. D. de Wit, D. Aletaha, N. Betteridge, J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. Hazes, M. Kouloumas, T. Kvien, X. Mariette, K. Pavelka, P. V. van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. Scott, T. Sokka-Isler, J. Wong, D. M. van der Heijde   +32 more
semanticscholar   +1 more source

Place of enalapril in treatment of patients with systemic lupus erythematosus and systemic sclerosis

Научно-практическая ревматология, 2003
Lupus erythematosus (SLE) and systemic sclerosis (SS). Methods. 45 SLE and 44 SS pts were included. Some of them received antirheumatic drugs in combination with enalapril other were treated with antirheumatic drugs only. The pts were examined before and
L K Kozlova, V V Bagirova
doaj   +1 more source

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period [PDF]

, 2019
BACKGROUND: Fluorescence optical imaging (FOI) enables visualization of inflammation in the hands in rheumatic joint diseases with currently a lack of long-term follow-up studies.
Backhaus, Marina, Burmester, Gerd-Rüdiger, Glimm, Anne-Marie, Haugen, Ida Kristin, Hermann, Sandra, Hoff, Paula, Häupl, Thomas, Le, Lien, Mansmann, Ulrich, Ohrndorf, Sarah, Sprenger, Lisa Ines   +10 more
core   +2 more sources

COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes

Arthritis & Rheumatology, 2020
To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID‐19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes.
Rebecca H. Haberman, R. Castillo, Alan Chen, D. Yan, Deborah Ramirez, Vaish Sekar, R. Lesser, G. Solomon, Andrea L Niemann, R. Blank, P. Izmirly, D. Webster, A. Ogdie, A. Troxel, S. Adhikari, J. Scher   +15 more
semanticscholar   +1 more source

Prescription pattern in patients with rheumatoid arthritis in a teaching tertiary care hospital

MAMC Journal of Medical Sciences, 2016
Objective: This study was conducted, with the aim to analyze the pattern of use of antirheumatic drugs in a Tertiary Care Hospital in Delhi, India. Methodology: The study was carried out in 150 patients who were on treatment with antirheumatic drugs at ...
Akhil Dahiya, Bhupinder Singh Kalra, Anmol Saini, Uma Tekur   +3 more
doaj   +1 more source